C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Purchases of Investments

Cash used to buy marketable securities and other investments.

C4 Therapeutics, Inc.NASDAQ: CCCC

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments growth accelerates

Q1 FY2026 purchases of investments of $40.81M (cash outflow) rose 59.2% year over year, ahead of the +19.8% change in trailing-twelve-month purchases of investments. Sequentially, it fell 69.3% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Purchases of investments amounted to 631.7% of revenue in FY2025, down 167.3 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +59.2% holds above the trailing-twelve-month pace of +19.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.81M-69.3% QoQ
Last fiscal yearDec 2025
-$227.07M-20.1% YoY
LTMMar 2026
-$242.25M+19.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.2%——
1 year-20.1%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(227.07M) USD
Year-over-year change
+20.1%

Purchases of Investments vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.8% is the 2nd highest of 6, against a peer median of -5.7%.
  • Purchases of investments amounts to 694.9% of revenue for CCCC, versus a peer median of 42.8%.
CCCC Competitors
Purchases of Investments for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$242.25M USD+19.8%+1.1%694.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$116.46M USD+88.1%-1.2%6528.2%
PEPGPepGen Inc.LTM Mar 2026$115.7M USD-5.7%——
CDXSCodexis, Inc.LTM Mar 2026$66.86M USD-8.6%+120.9%85.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 63.3M CHF-67.9%-39.5%—
OABIOmniAb, Inc.LTM Mar 2026$46M USD+1.9%-5.1%159.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CCCC) —-5.7%-3.1%42.8%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.